Cyclogest

Cyclogest

A brand name for PROGESTERONE.
Mentioned in ?
References in periodicals archive ?
Four hundred milligrams x2 daily progesterone vaginal suppositories (Cyclogest, Actavis, Devon, UK) were administered in the following 3 days when the endometrium reached a thickness of 8 mm or maximum.
No.KAP 1211 by DIA source Immuno Assays, Luteal support after egg collection was maintained by P vaginal pessaries (Cyclogest 400 mg) twice a day started after OPU.
Luteal support was maintained by P vaginal pessaries (Cyclogest 400mg) twice a day from the day of OPU.
Women were excluded if they had reaction to Cyclogest, multiple gestation, absence of fetus or fetal heart tone, uterine anomaly or fetal anomaly.
Our investigators bought the drugs (below) to put an end to the sale which included dozens of Menopur injections to stimulate the ovaries and Cyclogest which thickens the lining of the womb.
So up to week 13, the clinic prescribes progesterone in 400mg pessaries, called cyclogest. "There is doubt among gynaecologists over whether this treatment prevents miscarriages but in our experience it has helped a significant number of women who'd otherwise miscarry," says Mr Gordon.
She also tried Cyclogest, which is given as a suppository.
Females were included on the basis of; age 20-41 years duration of infertility more than 3 years both ovaries present with no morphological abnormalities normal ovulatory cycle (2535 days) body mass index (BMI)of 1835 kg/m2 basal FSH (day 2) serum level less than 9I U/ mL long protocol treatment with Gonadotrophin releasing hormone agonist (Gn Rh) stimulated with injection of recombinant follicle stimulating hormone (r FSH; Puregon) and prescribed vaginal progesterone support with 400 mg pessaries (cyclogest).
Luteal support was maintained by progesterone vaginal pessaries (Cyclogest 400 mg) twice a day from the day of OPU.
Using convenience sampling,323 consenting couples were enrolled meeting the inclusion criteria of female age 18-41, duration of infertility more than 2 years, both ovaries present with no morphological abnormalities, normal menstrual cycle (25-35 days), body mass index (BMI )of 18-27 kg/m2, basalFollicle-stimulating hormone(FSH) (day 2) serum levelless than 10IU/mL, elected for long protocol with Gonadotrophin releasing hormone agonist (GnRha), stimulated with injection of recombinant follicle stimulating hormone( rFSH; Puregon) and kept on progesterone support with400mg cyclogest pessaries.
Using convenience sampling, 106 consenting couples were registered on the basis of inclusion criteria; female age 18-41, duration of infertility more than 2 years, both ovaries present with no morphological abnormalities, normal ovulatory cycle (25-35 days), body mass index (BMI) of 18-27 kg/m2, basal follicle stimulating hormone (FSH) (day 2) serum level Less than 10mIU/mL, selected for long protocol with Gonadotrophin releasing hormone agonist (GnRH), stimulated with injection of recombinant FSH (Puregon) and kept on progesterone support with 400mg cyclogest pessaries.